Frankfurt - Delayed Quote EUR

Transgene SA (TGNA.F)

Compare
0.6700
-0.0430
(-6.03%)
As of 8:18:23 AM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
51.0000
1,184.0000
3,126.0000
9,993.0000
2,981.0000
Operating Expense
31,292.0000
29,859.0000
32,862.0000
33,739.0000
26,959.0000
Operating Income
-31,241.0000
-28,675.0000
-29,736.0000
-23,746.0000
-23,978.0000
Net Non Operating Interest Income Expense
7,404.0000
7,338.0000
-3,323.0000
3,734.0000
6,679.0000
Pretax Income
-22,911.0000
-22,328.0000
-32,804.0000
-19,536.0000
-17,231.0000
Net Income Common Stockholders
-22,911.0000
-22,328.0000
-32,804.0000
-19,536.0000
-17,231.0000
Diluted NI Available to Com Stockholders
-22,911.0000
-22,328.0000
-32,804.0000
-19,536.0000
-17,231.0000
Basic EPS
-0.22
-0.22
-0.33
-0.21
-0.21
Diluted EPS
-0.22
-0.22
-0.33
-0.21
-0.21
Basic Average Shares
101,169.9740
101,490.9090
99,501.9600
91,111.6490
83,841.3340
Diluted Average Shares
101,169.9740
101,490.9090
99,501.9600
91,111.6490
83,841.3340
Total Operating Income as Reported
-31,209.0000
-30,047.0000
-29,904.0000
-23,525.0000
-23,993.0000
Total Expenses
31,292.0000
29,859.0000
32,862.0000
33,739.0000
26,959.0000
Net Income from Continuing & Discontinued Operation
-22,911.0000
-22,328.0000
-32,804.0000
-19,536.0000
-17,231.0000
Normalized Income
-22,907.0000
-22,293.0000
-32,798.0000
-19,532.0000
-17,231.0000
Interest Income
--
--
--
4,198.0000
8,016.0000
Interest Expense
671.0000
168.0000
804.0000
464.0000
1,337.0000
Net Interest Income
7,404.0000
7,338.0000
-3,323.0000
3,734.0000
6,679.0000
EBIT
-22,240.0000
-22,160.0000
-32,000.0000
-19,072.0000
-15,894.0000
EBITDA
-20,861.0000
-20,588.0000
-30,314.0000
-16,551.0000
-14,108.0000
Reconciled Depreciation
1,379.0000
1,572.0000
1,686.0000
2,521.0000
1,786.0000
Net Income from Continuing Operation Net Minority Interest
-22,911.0000
-22,328.0000
-32,804.0000
-19,536.0000
-17,231.0000
Total Unusual Items Excluding Goodwill
-4.0000
-35.0000
-6.0000
-4.0000
--
Total Unusual Items
-4.0000
-35.0000
-6.0000
-4.0000
--
Normalized EBITDA
-20,857.0000
-20,553.0000
-30,308.0000
-16,547.0000
-14,108.0000
12/31/2020 - 5/3/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BM8.F BioMarin Pharmaceutical Inc.
57.60
-2.90%
 
A89.MU Adocia SAS A
6.04
0.00%
 
TRABI.BO Transgene Biotek Limited
4.4800
-1.75%
 
0RA2.IL Poxel S.A.
0.2940
-6.74%
 
LIANY LianBio
0.2025
0.00%
 
COOL.CN Core One Labs Inc.
0.1450
0.00%
 
ARCH.V Arch Biopartners Inc.
1.8400
-4.17%
 
LOBE.CN Lobe Sciences Ltd.
0.0250
0.00%
 
APS.TO Aptose Biosciences Inc.
0.3000
0.00%
 
DBV.PA DBV Technologies S.A.
0.8590
-1.83%